Is Calibrate Legit? What Our Registry Shows (2026)

Is Calibrate a real, safe GLP-1 telehealth company? Verified pricing history, its stated 30-day money-back guarantee, states served, eight named affiliated medical entities, and independent Trustpilot + BBB records, sourced from RangeYourself’s dated registry.

By RangeYourselfLast verified July 3, 2026

Yes, Calibrate is a real, operating GLP-1 telehealth company. RangeYourself has independently verified its pricing directly against its own site on July 3, 2026, and its refund/cancellation terms and states served are published on its own site. The evidence for that verdict is the dated verification below, not a claim we’re asking you to take on faith.

When we verified Calibrate

RangeYourself verified Calibrate’s price once, on July 3, 2026, directly against Calibrate’s own site. That is a single verification, not an ongoing trail, so treat it as a snapshot and confirm current pricing with Calibrate.

Pricing verification history

July 3, 2026: $250/mo

Refund and cancellation policy

Calibrate’s own stated policy: Money-back guarantee within first 30 days; pro-rated thereafter

Price and terms on file

Price: $199/mo membership + medication billed separately

Price last verified: July 3, 2026

States served

Calibrate ships to all 50 US states plus Washington, D.C., per its own site (verified July 3, 2026).

What the records show

Calibrate's Trustpilot and BBB records agree, a consistent, positive picture across both independent sources as of our check.

Trustpilot: 4.5★ (1,200 reviews) via Trustpilot, checked 2026-07-24

BBB: A+ rating (not accredited), BBB profile, checked 2026-07-24

Independently observed third-party data, not our own editorial score. Full methodology: GLP-1 Provider Reliability Report.

Verified programs that cost less than Calibrate

Calibrate’s own verified figure is $250/mo (verified all-in monthly price). Every program below carries a lower all-in monthly price that we verified on the provider’s own pricing page, ranked lowest first as of November 10, 2026.

1.Embody
$69/mo (limited-time promo), verified October 21, 2026
See pricing →
2.Yucca Health
$69/mo (12-month plan rate), verified November 7, 2026
See pricing →
3.HealthRX
$97/mo (12-month Subscribe & Save plan rate), verified November 10, 2026
See pricing →
4.Sprout Health
$99/mo (12-month plan rate), verified November 3, 2026
See pricing →
5.Strut Health
$99/mo (sublingual/oral starting price), verified September 28, 2026
See pricing →

Prices are each provider’s own published all-in monthly figure at the plan term shown, verified on the date listed. RangeYourself may earn a commission from some programs; that can only break an exact tie between verified equals and never changes the price order.

See Calibrate program → Read the full Calibrate review →

Frequently asked questions

Is Calibrate a real company?

Yes. RangeYourself has independently verified Calibrate's pricing directly against its own site (www.joincalibrate.com) on July 3, 2026, a single dated verification on file, and its refund policy and states served are published on its own site.

Is Calibrate FDA-approved?

Calibrate prescribes brand-name GLP-1 medication, which is FDA-approved.

Does Calibrate offer refunds or a guarantee?

Calibrate's own stated policy: Money-back guarantee within first 30 days; pro-rated thereafter This is the program's own policy, not a promise from RangeYourself, confirm current terms directly with Calibrate before enrolling.

What do independent reviews show for Calibrate?

4.5★ on Trustpilot from 1,200 reviews (checked 2026-07-24). A A+ BBB grade (not BBB Accredited) (checked 2026-07-24). This is third-party data, not RangeYourself's own editorial score.

Related guides

About compounded GLP-1 medicationsCompounded semaglutide and tirzepatide are not FDA-approved finished products. They are prepared by state-licensed 503A pharmacies or 503B outsourcing facilities and are not individually reviewed by the FDA for safety, effectiveness, or quality. Compounders describe these preparations as using the same active ingredient as the approved medicines; the FDA has warned that some compounded products use salt forms, semaglutide sodium or semaglutide acetate, that it considers different active ingredients from the approved drug, and has issued warning letters over marketing that presents a compounded preparation as interchangeable with an approved one. The FDA declared the semaglutide shortage resolved on February 21, 2025 and the tirzepatide shortage resolved in December 2024, so the shortage-era pathway for broad compounding of these drugs has ended. Compounding now proceeds under the ordinary rules: a 503A pharmacy compounding for an individual patient on a prescription, or a 503B outsourcing facility, which compounds in bulk under CGMP and FDA registration rather than per patient. Those rules generally do not cover a product that is “essentially a copy” of an approved drug unless a prescriber documents a change that makes a significant difference for an individual patient. Talk to a clinician about contraindications including personal or family history of medullary thyroid carcinoma or MEN 2. RangeYourself does not provide medical advice, does not guarantee a prescription, and does not guarantee weight-loss results.

RangeYourself is reader-supported. We may earn a commission when you click on certain links, at no extra cost to you. Editorial recommendations are made independently. This legitimacy check reflects registry data verified through July 3, 2026 and may change.